Back to top
more

Accuray (ARAY)

(Delayed Data from NSDQ)

$1.30 USD

1.30
397,986

+0.01 (0.78%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $1.30 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Will Accuray (ARAY) Gain on Rising Earnings Estimates?

by Zacks Equity Research

Accuray (ARAY) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Zacks Equity Research

What Makes Accuray (ARAY) a New Strong Buy Stock

by Zacks Equity Research

Accuray (ARAY) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Nitish Marwah headshot

New Strong Buy Stocks for May 1st

by Nitish Marwah

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today.

Zacks Equity Research

Accuray (ARAY) Earnings and Revenues Beat Estimates in Q3

by Zacks Equity Research

Accuray's (ARAY) gross orders were driven by solid EMEA momentum in Q3.

Zacks Equity Research

Accuray (ARAY) Beats Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Accuray (ARAY) delivered earnings and revenue surprises of 200.00% and 3.21%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Sriparna Ghosal headshot

Here's Why You Should Retain Accuray in Your Portfolio

by Sriparna Ghosal

Investor confidence remains high in Accuray (ARAY) stock, thanks to solid prospects.

Zacks Equity Research

Why You Should Invest in Cardinal Health (CAH) Stock Now

by Zacks Equity Research

Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment, diversified product portfolio and strategic buyouts.

Zacks Equity Research

Here's Why You Should Invest in DaVita (DVA) Stock Right Now

by Zacks Equity Research

DaVita (DVA) continues to gain traction from strong international foothold, strategic buyout of dialysis centers and DaVita Kidney Care.

Zacks Equity Research

Here's Why You Should Hold On to PerkinElmer (PKI) Stock Now

by Zacks Equity Research

PerkinElmer (PKI) expects to witness foreign exchange headwinds in 2020.

    Zacks Equity Research

    Here's Why You Should Hold On to Inogen (INGN) Stock for Now

    by Zacks Equity Research

    Inogen (INGN) expects to report a loss per share in the first quarter of 2020.

    Zacks Equity Research

    Here's Why You Should Retain Merit Medical (MMSI) Stock Now

    by Zacks Equity Research

    Merit Medical (MMSI) continues to benefit from growing product pipeline, strong R&D focus and strategic acquisitions.

      Zacks Equity Research

      Here's Why Investors Should Buy Masimo (MASI) Stock Now

      by Zacks Equity Research

      Masimo (MASI) sees a slew of developments lately.

        Zacks Equity Research

        Masimo & University Hospitals Unite for Patient Monitoring

        by Zacks Equity Research

        Masimo (MASI) sees a plethora of developments lately.

          Zacks Equity Research

          PRA Health's New Program to Lend Support to Healthcare System

          by Zacks Equity Research

          PRA Health's (PRAH) COVID-19 Monitoring Program will allow individuals to connect with a healthcare professional remotely while maintaining social distancing.

          Zacks Equity Research

          Here's Why You Should Hold on to NextGen Healthcare Stock Now

          by Zacks Equity Research

          NextGen Healthcare (NXGN) continues to benefit from growing RCM and EHR markets, and robust demand for other NextGen solutions.

          Zacks Equity Research

          Masimo's Latest Buyout to Boost Respiratory Product Spectrum

          by Zacks Equity Research

          Masimo (MASI) expects the transaction to be neutral to 2020 earnings.

          Zacks Equity Research

          Here's Why You Should Hold Onto Baxter (BAX) Stock for Now

          by Zacks Equity Research

          Baxter (BAX) issues strong guidance for the first quarter of 2020.

          Zacks Equity Research

          Accuray Enters Oversold Territory

          by Zacks Equity Research

          Accuray has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

          Zacks Equity Research

          Varian's (VAR) ProBeam Compact Treats First Patient at UAB

          by Zacks Equity Research

          Varian's (VAR) flagship ProBeam platform is seeing multiple developments of late.

          Zacks Equity Research

          Here's Why You Should Retain Cerner (CERN) Stock for Now

          by Zacks Equity Research

          Cerner (CERN) is gaining traction from prudent strategic deals and big data based EHR system. However, weak margin remains a woe.

          Zacks Equity Research

          NextGen's New Platform Set to Improve Patient Engagement

          by Zacks Equity Research

          The availability of NextGen's (NXGN) Patient Experience Platform is likely to enable high-quality healthcare and drive patient engagement.

          Zacks Equity Research

          HealthEquity (HQY) Q4 Earnings and Revenues Top Estimates

          by Zacks Equity Research

          HealthEquity's (HQY) fiscal fourth-quarter earnings benefit from higher revenues and solid performing Service, Custodial and Interchange segments.

          Zacks Equity Research

          Baxter (BAX) Q4 Earnings Beat Estimates, Revenues In Line

          by Zacks Equity Research

          Baxter's (BAX) fourth-quarter earnings benefit from higher revenues, solid segmental performance and growth in APAC.

          Zacks Equity Research

          Here's Why You Should Hold Onto Varian Medical Stock Now

          by Zacks Equity Research

          Varian Medical (VAR) gains from solid prospects of its core Oncology Systems unit.

          Zacks Equity Research

          Here's Why You Should Buy Cooper Companies (COO) Stock Now

          by Zacks Equity Research

          Cooper Companies (COO) lifts adjusted earnings per share view for fiscal 2020.